. .. Généralités,

B. , Classification de Lublin et Reingold, 1996.

C. Epidémiologie-de-la-forme-secondaire-progressive and .. .. ,

D. Diagnostic-de-la-forme-secondaire-progressive and .. .. ,

. .. Activité,

A. Activité,

B. Activité,

C. Activité,

. , Activité et progression, concepts non exclusifs

B. , Formes progressives actives: revue de littérature

C. , Formes progressives actives: perspectives thérapeutiques

. .. Deuxième-partie-:-article,

M. .. Material,

. .. Results,

. .. Discussion,

. .. Conclusion, , p.61

. .. References, , p.61

T. .. Conclusion,

B. .. ,

F. D. Lublin, S. C. Reingold, J. A. Cohen, G. R. Cutter, P. S. Sorensen et al., Defining the clinical course of multiple sclerosis: The 2013 revisions

, Neurology, vol.83, issue.3, pp.278-86, 2014.

C. Lucchinetti, W. Brück, J. Parisi, B. Scheithauer, M. Rodriguez et al., Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination, Annals of Neurology, vol.47, issue.6, pp.707-724, 2000.

F. Cotton, H. L. Weiner, F. A. Jolesz, and C. Guttmann, MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals, Neurology, vol.60, issue.4, pp.640-646, 2003.

P. Soldán, M. M. Novotna, M. , A. Zeid, N. Kale et al., Relapses and disability accumulation in progressive multiple sclerosis, Neurology, vol.84, issue.1, pp.81-89, 2015.

K. Ahrweiller, Relapses in patients with secondary progressive MS: a matter of disease duration or age?, 7th Joint ECTRIMS-ACTRIMS Meeting, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01715985

N. Tubridy, A. J. Coles, P. Molyneux, D. A. Compston, F. Barkhof et al., Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features, Brain, vol.121, pp.225-256, 1998.

D. Kidd, J. W. Thorpe, B. E. Kendall, G. J. Barker, D. H. Miller et al., MRI dynamics of brain and spinal cord in progressive multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.60, issue.1, pp.15-24, 1996.

A. J. Thompson, A. G. Kermode, D. Wicks, D. G. Macmanus, B. E. Kendall et al., Major differences in the dynamics of primary and secondary progressive multiple sclerosis, Ann Neurol, vol.29, issue.1, pp.53-62, 1991.

M. Filippi, P. Rossi, A. Campi, B. Colombo, C. Pereira et al., Serial Contrast-Enhanced MR in Patients with Multiple Sclerosis and Varying Levels of Disability, AJNR Am J Neuroradiol, vol.18, pp.1549-1556, 1997.

P. D. Molyneux, M. Filippi, F. Barkhof, C. Gasperini, T. A. Yousry et al., Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis, Ann Neurol, vol.43, issue.3, pp.332-341, 1998.

N. Tubridy, H. J. Ader, F. Barkhof, A. J. Thompson, and D. H. Miller, Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups, J Neurol Neurosurg Psychiatry, vol.64, issue.1, pp.50-55, 1998.

Y. Zhao, A. J. Petkau, A. Traboulsee, A. Riddehough, and D. Li, Does MRI lesion activity regress in secondary progressive multiple sclerosis? Mult Scler, 2010.

X. Montalban, S. L. Hauser, L. Kappos, D. L. Arnold, A. Bar-or et al., Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
URL : https://hal.archives-ouvertes.fr/hal-01793440

, N Engl J Med, vol.376, issue.3, pp.209-229, 201719.

K. Hawker, P. O'connor, M. S. Freedman, P. A. Calabresi, J. Antel et al., Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial, Ann Neurol, vol.66, issue.4, pp.460-71, 2009.

L. Kappos, A. Bar-or, B. Cree, R. J. Fox, G. Giovannoni et al., Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. The Lancet, vol.391, pp.1263-73, 2018.

M. Debouverie, S. Pittion-vouyovitch, S. Louis, F. Guillemin, and . Group, Natural history of multiple sclerosis in a population-based cohort, European Journal of Neurology, vol.15, issue.9, pp.916-937, 2008.

H. El-adssi, M. Debouverie, F. Guillemin, and . Group, Estimating the prevalence and incidence of multiple sclerosis in the Lorraine region, France, by the capture-recapture method, Mult Scler, vol.18, issue.9, pp.1244-50, 2012.

C. Confavreux, D. A. Compston, O. R. Hommes, W. I. Mcdonald, and A. J. Thompson, EDMUS, a European database for multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.55, issue.8, pp.671-677, 1992.

C. M. Poser, D. W. Paty, L. Scheinberg, W. I. Mcdonald, F. A. Davis et al., New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

, Ann Neurol, vol.13, issue.3, pp.227-258, 1983.

W. I. Mcdonald, A. Compston, G. Edan, D. Goodkin, H. P. Hartung et al., Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, Ann Neurol, 2001.

C. H. Polman, S. C. Reingold, G. Edan, M. Filippi, H. Hartung et al., Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria, Ann Neurol, vol.58, issue.6, pp.840-846, 2005.
DOI : 10.1002/ana.22366

URL : http://europepmc.org/articles/pmc3084507?pdf=render

C. H. Polman, S. C. Reingold, B. Banwell, M. Clanet, J. A. Cohen et al., Diagnostic criteria for multiple sclerosis, 2010.

, Ann Neurol, vol.69, issue.2, pp.292-302, 2011.

J. F. Kurtzke, Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, vol.33, issue.11, pp.1444-52, 1983.

F. Barkhof, The clinico-radiological paradox in multiple sclerosis revisited, Curr Opin Neurol, vol.15, issue.3, pp.239-284, 2002.

T. Kalincik, V. Vivek, V. Jokubaitis, M. Trojano, and G. Izquierdo, Sex as a determinant of relapse incidence and progressive course of multiple sclerosis

, Brain, vol.136, pp.3609-3626, 2013.

C. Confavreux, S. Vukusic, T. Moreau, and P. Adeleine, Relapses and progression of disability in multiple sclerosis, N Engl J Med, vol.343, issue.20, pp.1430-1438, 2000.

. Basha-m-a.-a, Does MR spectroscopy of normal-appearing cervical spinal cord in patients with multiple sclerosis have diagnostic value in assessing disease progression? A prospective comparative analysis, Clin Radiol, 2018.

A. Scalfari, A. Neuhaus, A. Degenhardt, G. P. Rice, P. A. Muraro et al., The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability, Brain, vol.133, pp.1914-1943, 2010.

H. Tremlett, Y. Zhao, J. Joseph, V. Devonshire, . Ubcms-clinic et al.,

, J Neurol Neurosurg Psychiatry, vol.79, issue.12, pp.1368-74, 2008.

S. Foulon, G. Maura, A. F. Debouverie, M. Moreau, and T. , Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data, Journal of Neurology, vol.264, issue.6, pp.1185-92, 2017.

A. Fromont, C. Binquet, E. Sauleau, R. Despalins, and F. Rollot, National estimate of multiple sclerosis incidence in France, 2001.

, Multiple Sclerosis Journal, vol.18, issue.8, pp.1108-1123, 2012.

M. Debouverie, Gender as a prognostic factor and its impact on the incidence of multiple sclerosis in Lorraine, France, Journal of the Neurological Sciences, vol.286, issue.1-2, pp.14-21, 2009.

A. Fromont, C. Binquet, E. A. Sauleau, I. Fournel, A. Bellisario et al., Geographic variations of multiple sclerosis in France, Brain, vol.133, issue.7, pp.1889-99, 2010.

S. Vukusic, V. Van-bockstael, S. Gosselin, and C. Confavreux, Regional variations in the prevalence of multiple sclerosis in French farmers, Neurosurgery & Psychiatry, vol.78, issue.7, pp.707-716, 2006.

E. Leray, T. Moreau, A. Fromont, and G. Edan, Epidemiology of multiple sclerosis, Revue Neurologique, vol.172, issue.1, pp.3-13, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01255824

M. C. Confavreux, Change of Demographic Data over time in Multiple Sclerosis.The Lyon Multiple Sclerosis Cohort Experience, Multiple Sclerosis Journal, vol.14

L. Belbasis, V. Bellou, E. Evangelou, J. Ioannidis, and I. Tzoulaki, Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses

, The Lancet Neurology, vol.14, pp.263-73, 2015.

F. D. Lublin and S. C. Reingold, National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis*. Defining the clinical course of multiple sclerosis: Results of an international survey, Neurology, vol.46, issue.4, pp.907-918, 1996.

C. Confavreux, G. Aimard, and M. Devic, Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients, Brain, vol.103, issue.2, pp.281-300, 1980.

M. Debouverie, S. Louis, S. Pittion-vouyovitch, T. Roederer, and H. Vespignani, Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France, Journal of Neurology, vol.254, issue.10, pp.1370-1375, 2007.

C. Binquet, C. Quantin, L. Teuff, G. Pagliano, J. F. Abrahamowicz et al., The Prognostic Value of Initial Relapses on the Evolution of Disability in Patients with Relapsing-Remitting Multiple Sclerosis, Neuroepidemiology, vol.27, issue.1, pp.45-54, 2006.

B. Runmarker and O. Andersen, Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up, Brain, vol.116, issue.1, pp.117-151, 1993.

H. Tremlett, Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities, Journal of Neurology, vol.256, issue.3, pp.374-81, 2009.
DOI : 10.1007/s00415-009-0039-7

M. Koch, E. Kingwell, P. Rieckmann, H. Tremlett, U. Ms-clinic et al., The natural history of secondary progressive multiple sclerosis, Neurosurgery & Psychiatry, vol.81, issue.9, pp.1039-1082, 2010.

S. Vukusic and C. Confavreux, Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis, Journal of the Neurological Sciences, vol.206, issue.2, pp.135-142, 2003.

M. Koch, D. Keyser, J. Tremlett, and H. , Timing of birth and disease progression in multiple sclerosis, Multiple Sclerosis Journal, vol.14, issue.6, pp.793-801, 2008.

J. M. Minderhoud, J. H. Hoeven, and A. Prange, Course and prognosis of chronic progressive multiple sclerosis: Results of an epidemiological study

, Acta Neurologica Scandinavica, vol.78, issue.1, pp.10-15, 1988.

B. Stankoff, S. Mrejen, A. Tourbah, B. Fontaine, O. Lyon-caen et al., Age at onset determines the occurrence of the progressive phase of multiple sclerosis, Neurology, vol.68, issue.10, pp.779-81, 2007.

M. Koch, J. Mostert, D. Heersema, D. Keyser, and J. , Progression in multiple sclerosis: Further evidence of an age dependent process, Journal of the Neurological Sciences, 2007.

H. Tremlett, Y. Zhao-null, and V. Devonshire, Natural history of secondary-progressive multiple sclerosis, Mult Scler, vol.14, issue.3, pp.314-338, 2008.
DOI : 10.1177/1352458507084264

I. Katz-sand, S. Krieger, C. Farrell, and A. E. Miller, Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis

C. H. Polman, S. C. Reingold, B. Banwell, M. Clanet, J. A. Cohen et al., Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria, Annals of Neurology, vol.69, issue.2, pp.292-302, 2011.

J. K. Swanton, A. Rovira, M. Tintore, D. R. Altmann, F. Barkhof et al., MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. The Lancet Neurology, vol.6, pp.677-86, 2007.

A. J. Thompson, B. L. Banwell, F. Barkhof, W. M. Carroll, T. Coetzee et al., Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria, Lancet Neurol, vol.17, issue.2, pp.162-73, 2018.

J. Lorscheider, Defining secondary progressive multiple sclerosis, Brain, vol.139, issue.9, pp.2395-405, 2016.

. , Aspects cliniques, physiopathologiques, et thérapeutiques de la sclérose en plaques

T. Kalincik, K. Buzzard, V. Jokubaitis, M. Trojano, and G. Izquierdo, Risk of relapse phenotype recurrence in multiple sclerosis

, Multiple Sclerosis Journal, vol.20, issue.11, pp.1511-1533, 2014.

B. Popescu and C. F. Lucchinetti, Pathology of Demyelinating Diseases. Annual Review of Pathology: Mechanisms of Disease, vol.7, pp.185-217, 2012.

C. Lucchinetti, W. Brück, J. Parisi, B. Scheithauer, M. Rodriguez et al., Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination, Annals of Neurology, vol.47, issue.6, pp.707-724, 2000.

J. M. Frischer, S. D. Weigand, Y. Guo, N. Kale, J. E. Parisi et al., Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque: Dynamic Nature of MS Plaque, Annals of Neurology, vol.78, issue.5, pp.710-731, 2015.

A. Minagar and J. S. Alexander, Blood-brain barrier disruption in multiple sclerosis, Multiple Sclerosis Journal, vol.9, issue.6, pp.540-549, 2003.

D. M. Chari, Remyelination In Multiple Sclerosis, International Review of Neurobiology, vol.79, pp.589-620

P. Patrikios, C. Stadelmann, A. Kutzelnigg, H. Rauschka, M. Schmidbauer et al., Remyelination is extensive in a subset of multiple sclerosis patients

, Brain, vol.129, issue.12, pp.3165-72, 2006.

A. Bitsch, Acute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation, Brain, vol.123, issue.6, pp.1174-83, 2000.

B. D. Trapp, J. Peterson, R. M. Ransohoff, R. Rudick, S. Mörk et al., Axonal Transection in the Lesions of Multiple Sclerosis

, New England Journal of Medicine, vol.338, issue.5, pp.278-85, 1998.

C. Bjartmar, J. Wujek, and B. Trapp, Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease, Journal of the Neurological Sciences, vol.206, issue.2, pp.165-71, 2003.

D. S. Meier and C. Guttmann, Time-series analysis of MRI intensity patterns in multiple sclerosis, NeuroImage, vol.20, issue.2, pp.1193-209, 2003.

F. Cotton, H. L. Weiner, F. A. Jolesz, and C. Guttmann, MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals, Neurology, vol.60, issue.4, pp.640-646, 2003.

M. A. Sahraian, Black holes in multiple sclerosis: definition, evolution, and clinical correlations: Black holes in MS

, Acta Neurologica Scandinavica, vol.122, issue.1, pp.1-8, 2009.

F. Barkhof, P. Scheltens, S. T. Frequin, J. J. Nauta, M. W. Tas et al., Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity, American Journal of Roentgenology, vol.159, issue.5, pp.1041-1048, 1992.

M. Filippi, M. A. Rocca, G. Martino, M. A. Horsfield, and G. Comi, Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis, Annals of Neurology, vol.43, issue.6, pp.809-823, 1998.

M. C. Tartaglia, S. Narayanan, D. Stefano, N. Arnaoutelis, R. Antel et al., Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis, Journal of Neurology, vol.249, issue.10, pp.1382-90, 2002.

C. Confavreux and S. Vukusic, Natural history of multiple sclerosis: a unifying concept, Brain, vol.129, issue.3, pp.606-622, 2006.

N. D. Chiaravalloti and J. Deluca, Cognitive impairment in multiple sclerosis. The Lancet Neurology, vol.7, pp.1139-51, 2008.

B. Bagert, P. Camplair, and D. Bourdette, Cognitive Dysfunction in Multiple Sclerosis

. Mol-diag-ther, , vol.16, pp.445-55, 2002.

R. A. Marrie, S. Reingold, J. Cohen, O. Stuve, M. Trojano et al., The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review

, Multiple Sclerosis Journal, vol.21, issue.3, pp.305-322, 2015.

A. Hennessey, N. P. Robertson, and R. Swingler, Compston D a. S. Urinary, faecal and sexual dysfunction in patients with multiple sclerosis, J Neurol, vol.246, issue.11, pp.1027-1059, 1999.

R. Zivadinov, M. Zorzon, A. Bosco, L. M. Bragadin, R. Moretti et al., Sexual dysfunction in multiple sclerosis: II

, Mult Scler, vol.5, issue.6, pp.428-459, 1999.

J. F. Kurtzke, Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, vol.33, issue.11, pp.1444-52, 1983.

G. R. Cutter, M. L. Baier, R. A. Rudick, D. L. Cookfair, J. S. Fischer et al., Development of a multiple sclerosis functional composite as a clinical trial outcome measure

, Brain, vol.122, pp.871-82, 1999.

J. W. Prineas, E. E. Kwon, E. Cho, L. R. Sharer, M. H. Barnett et al., Immunopathology of secondary-progressive multiple sclerosis, Annals of Neurology, vol.50, issue.5, pp.646-57, 2001.

I. V. Allen and S. R. Mckeown, A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis, Journal of the Neurological Sciences, vol.41, issue.1, pp.81-91, 1979.

I. V. Allen, S. Mcquaid, M. Mirakhur, and G. Nevin, Pathological abnormalities in the normal-appearing white matter in multiple sclerosis, Neurol Sci, vol.22, issue.2, pp.141-145, 2001.

A. Kutzelnigg, C. F. Lucchinetti, C. Stadelmann, W. Brück, H. Rauschka et al., Cortical demyelination and diffuse white matter injury in multiple sclerosis, Brain, vol.128, pp.2705-2717, 2005.

J. J. Geurts and F. Barkhof, Grey matter pathology in multiple sclerosis. The Lancet Neurology, vol.7, pp.841-51, 2008.

C. P. Gilmore, I. Donaldson, L. Bo, T. Owens, J. Lowe et al., Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord, Neurosurgery & Psychiatry, vol.80, issue.2, pp.182-189, 2009.

L. Bø, Demyelination in the Cerebral Cortex of Multiple Sclerosis Patients, Journal of Neuropathology & Experimental Neurology, vol.62, issue.7, pp.723-755, 2003.

J. W. Peterson, Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions: Cortical Lesions in MS, Annals of Neurology, vol.50, issue.3, pp.389-400, 2001.

L. Bø, C. A. Vedeler, H. Nyland, B. D. Trapp, and S. J. Mørk, Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration

, Multiple Sclerosis Journal, vol.9, issue.4, pp.323-354, 2003.

B. Serafini, B. Rosicarelli, R. Magliozzi, E. Stigliano, and F. Aloisi, Detection of Ectopic B-cell Follicles with Germinal Centers in the Meninges of Patients with Secondary Progressive Multiple Sclerosis. Brain Pathology, vol.14, pp.164-74, 2004.

R. Magliozzi, O. Howell, A. Vora, B. Serafini, R. Nicholas et al., Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology, Brain, vol.130, pp.1089-104, 2007.

R. Magliozzi, O. W. Howell, C. Reeves, F. Roncaroli, R. Nicholas et al., A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis

, Ann Neurol, vol.68, issue.4, pp.477-93, 2010.

E. Kooi, J. Geurts, J. Van-horssen, L. Bø, and P. Van-der-valk, Meningeal inflammation is not associated with cortical demyelination in chronic multiple sclerosis

, J Neuropathol Exp Neurol, vol.68, issue.9, pp.1021-1029, 2009.

B. Ferguson, M. K. Matyszak, M. M. Esiri, and V. H. Perry, Axonal damage in acute multiple sclerosis lesions, Brain, vol.120, pp.393-402, 1997.

J. Rawes, V. Calabrese, O. Khan, and G. Devries, Antibodies to the axolemma-enriched fraction in the cerebrospinal fluid and serum of patients with multiple sclerosis and other neurological diseases, Multiple Sclerosis Journal, vol.3, issue.6, pp.363-372, 1997.

H. M. Gibbons and M. Dragunow, Microglia induce neural cell death via a proximity-dependent mechanism involving nitric oxide, Brain Research, vol.1084, issue.1, pp.1-15, 2006.

S. G. Waxman, Acquired channelopathies in nerve injury and MS, Neurology, vol.56, issue.12, pp.1621-1628, 2001.

D. J. Mahad, I. Ziabreva, G. Campbell, N. Lax, K. White et al., Mitochondrial changes within axons in multiple sclerosis, Brain, vol.132, pp.1161-74, 2009.

M. Stagi, P. Gorlovoy, S. Larionov, K. Takahashi, and H. Neumann, Unloading kinesin transported cargoes from the tubulin track via the inflammatory c-Jun N-terminal kinase pathway, FASEB J, vol.20, issue.14, pp.2573-2578, 2006.

G. C. Deluca, The contribution of demyelination to axonal loss in multiple sclerosis, Brain, vol.129, issue.6, pp.1507-1523, 2006.

V. Sethi, T. A. Yousry, N. Muhlert, R. M. Golay, X. Wheeler-kingshott et al., Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI, J Neurol Neurosurg Psychiatry, vol.83, issue.9, pp.877-82, 2012.

A. Seewann, E. Kooi, S. D. Roosendaal, P. Pouwels, M. P. Wattjes et al., Postmortem verification of MS cortical lesion detection with 3D DIR, Neurology, vol.78, issue.5, pp.302-310, 2012.

M. Calabrese, M. A. Rocca, M. Atzori, I. Mattisi, A. Favaretto et al., A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis

, Ann Neurol, vol.67, issue.3, pp.376-83, 2010.

M. Calabrese, M. Filippi, M. Rovaris, I. Mattisi, V. Bernardi et al., Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study, Neuroimage, vol.42, issue.4, pp.1324-1332, 2008.

M. Calabrese, D. Stefano, N. Atzori, M. Bernardi, V. Mattisi et al., Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis, Arch Neurol, vol.64, issue.10, pp.1416-1438, 2007.

M. Absinta, L. Vuolo, A. Rao, G. Nair, P. Sati et al., Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis, Neurology, vol.85, issue.1, pp.18-28, 2015.

R. Zivadinov, D. P. Ramasamy, M. Vaneckova, S. Gandhi, A. Chandra et al., Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study, p.2017

A. Bitsch, H. Bruhn, V. Vougioukas, A. Stringaris, H. Lassmann et al., Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy, AJNR Am J Neuroradiol, vol.20, issue.9, pp.1619-1646, 1999.

D. L. Arnold, G. T. Riess, P. M. Matthews, G. S. Francis, D. L. Collins et al., Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis, Ann Neurol, vol.36, issue.1, pp.76-82, 1994.

J. Sun, H. Song, Y. Yang, K. Zhang, X. Gao et al., Metabolic changes in normal appearing white matter in multiple sclerosis patients using multivoxel magnetic resonance spectroscopy imaging, Medicine, vol.96, issue.14, p.6534, 2017.

L. Fu, P. M. Matthews, D. Stefano, N. Worsley, K. J. Narayanan et al., Imaging axonal damage of normal-appearing white matter in multiple sclerosis, Brain, 1998.

A. Tourbah, J. L. Stievenart, O. Gout, B. Fontaine, R. Liblau et al., Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis, Neurology, vol.53, issue.5, pp.1091-1098, 1999.
DOI : 10.1212/wnl.53.5.1091

J. H. Van-waesberghe, W. Kamphorst, D. Groot, C. J. Van-walderveen, M. A. Castelijns et al., Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability, Ann Neurol, vol.46, issue.5, pp.747-54, 1999.

Z. Liu, M. Pardini, Ö. Yaldizli, V. Sethi, N. Muhlert et al., Magnetization transfer ratio measures in normal-appearing white matter show periventricular gradient abnormalities in multiple sclerosis

, Brain, vol.138, pp.1239-1285, 2015.

L. K. Fisniku, D. T. Chard, J. S. Jackson, V. M. Anderson, D. R. Altmann et al., Gray matter atrophy is related to long-term disability in multiple sclerosis, Ann Neurol, vol.64, issue.3, pp.247-54, 2008.

E. Portaccio, V. Zipoli, B. Goretti, D. Stefano, N. Amato et al., Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS
DOI : 10.1016/j.jns.2009.04.031

, 2):223; author reply, J Neurol Sci, vol.284, issue.1, pp.223-224, 2009.

C. M. Dalton, D. T. Chard, G. R. Davies, K. A. Miszkiel, D. R. Altmann et al., Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes

, Brain, vol.127, pp.1101-1108, 2004.

R. Benedict, Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis, J Neuroimaging, vol.14, pp.36-45, 2004.

J. Furby, T. Hayton, D. Altmann, R. Brenner, J. Chataway et al., A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis, J Neurol, vol.257, issue.9, pp.1508-1524, 2010.

R. Zivadinov and R. Bakshi, Central nervous system atrophy and clinical status in multiple sclerosis, J Neuroimaging, vol.14, issue.3, pp.27-35, 2004.

N. Bergsland, R. Zivadinov, M. G. Dwyer, B. Weinstock-guttman, and R. H. Benedict, Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients

, Mult Scler, vol.22, issue.10, pp.1327-1363, 2016.

M. K. Houtchens, R. Benedict, R. Killiany, J. Sharma, Z. Jaisani et al., Thalamic atrophy and cognition in multiple sclerosis, Neurology, vol.69, issue.12, pp.1213-1236, 2007.

M. Koini, M. Filippi, M. A. Rocca, T. Yousry, O. Ciccarelli et al., Correlates of Executive Functions in Multiple Sclerosis Based on Structural and Functional MR Imaging: Insights from a Multicenter Study, Radiology, vol.280, issue.3, pp.869-79, 2016.

C. Lukas, M. H. Sombekke, B. Bellenberg, H. K. Hahn, V. Popescu et al., Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients, Radiology, vol.269, issue.2, pp.542-52, 2013.

J. Furby, T. Hayton, V. Anderson, D. Altmann, R. Brenner et al., Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis, Mult Scler, vol.14, issue.8, pp.1068-75, 2008.

P. Valsasina, M. A. Rocca, M. A. Horsfield, M. Absinta, R. Messina et al., Regional cervical cord atrophy and disability in multiple sclerosis: a voxel-based analysis, Radiology, vol.266, issue.3, pp.853-61, 2013.

X. Lin, C. R. Tench, B. Turner, L. D. Blumhardt, and C. S. Constantinescu, Spinal cord atrophy and in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial, J Neurol Neurosurg Psychiatry, vol.74, issue.8, pp.1090-1094, 2003.

F. D. Lublin, S. C. Reingold, J. A. Cohen, G. R. Cutter, P. S. Sørensen et al., Defining the clinical course of multiple sclerosis: the 2013 revisions, Neurology, vol.83, issue.3, pp.278-86, 2014.

C. Confavreux, S. Vukusic, T. Moreau, and P. Adeleine, Relapses and progression of disability in multiple sclerosis, N Engl J Med, vol.343, issue.20, pp.1430-1438, 2000.

P. Soldán, M. M. Novotna, M. , A. Zeid, N. Kale et al., Relapses and disability accumulation in progressive multiple sclerosis, Neurology, vol.84, issue.1, pp.81-89, 2015.

K. Ahrweiller, Relapses in patients with secondary progressive MS: a matter of disease duration or age?, 7th Joint ECTRIMS-ACTRIMS Meeting, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01715985

J. A. Cohen, G. R. Cutter, J. S. Fischer, A. D. Goodman, F. R. Heidenreich et al., Benefit of interferon beta-1a on MSFC progression in secondary progressive MS, Neurology, vol.59, issue.5, pp.679-87, 2002.

K. Hawker, P. O'connor, M. S. Freedman, P. A. Calabresi, J. Antel et al., Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial, Ann Neurol, vol.66, issue.4, pp.460-71, 2009.

R. Orbach, Z. Zhao, Y. Wang, O. 'neill, G. Cadavid et al., Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials

, PLoS ONE, vol.7, issue.10, p.45409, 2012.

N. Tubridy, A. J. Coles, P. Molyneux, D. A. Compston, F. Barkhof et al., Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features, Brain, vol.121, pp.225-256, 1998.

D. Kidd, J. W. Thorpe, B. E. Kendall, G. J. Barker, D. H. Miller et al., MRI dynamics of brain and spinal cord in progressive multiple sclerosis

, J Neurol Neurosurg Psychiatry, vol.60, issue.1, pp.15-24, 1996.

A. J. Thompson, A. G. Kermode, D. Wicks, D. G. Macmanus, B. E. Kendall et al., Major differences in the dynamics of primary and secondary progressive multiple sclerosis, Ann Neurol, vol.29, issue.1, pp.53-62, 1991.

M. Filippi, Serial contrast-enhanced MR in patients with multiple sclerosis and varying levels of disability, American Journal of Neuroradiology, vol.18, issue.8, pp.1549-1556, 1997.

P. D. Molyneux, M. Filippi, F. Barkhof, C. Gasperini, T. A. Yousry et al., Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis, Ann Neurol, vol.43, issue.3, pp.332-341, 1998.

N. Tubridy, H. J. Ader, F. Barkhof, A. J. Thompson, and D. H. Miller, Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups, J Neurol Neurosurg Psychiatry, vol.64, issue.1, pp.50-55, 1998.

Y. Zhao, A. J. Petkau, A. Traboulsee, A. Riddehough, and D. Li, Does MRI lesion activity regress in secondary progressive multiple sclerosis? Mult Scler, vol.16, pp.434-476, 2010.
DOI : 10.1177/1352458509359726

S. M. Leary, D. H. Miller, V. L. Stevenson, P. A. Brex, D. T. Chard et al., Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial, Jan, vol.14, issue.1, pp.44-51, 2003.
DOI : 10.1212/wnl.60.1.44

X. Montalban, J. Sastre-garriga, M. Tintoré, L. Brieva, F. X. Aymerich et al., A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis, Mult Scler, 2009.

H. Panitch, A. Miller, D. Paty, and B. Weinshenker, North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS:results from a 3-year controlled study, Neurology, vol.63, issue.10, pp.1788-95, 2004.

D. K. Li, G. J. Zhao, and D. W. Paty, University of British Columbia MS/MRI Analysis Research Group. The SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results, Neurology, vol.56, issue.11, pp.1505-1518, 2001.

J. S. Wolinsky, P. A. Narayana, O. Connor, P. Coyle, P. K. Ford et al., Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial, Ann Neurol, vol.61, issue.1, pp.14-24, 2007.

F. Lublin, D. H. Miller, M. S. Freedman, B. Cree, J. S. Wolinsky et al., Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial, Lancet, vol.387, pp.1075-84, 2016.
DOI : 10.1016/s0140-6736(15)01314-8

URL : https://hal.archives-ouvertes.fr/hal-01880998

, Subgroup analyses of natalizumab treatment response in ASCEND, a multicenter, a double-blind, placebo-controlled, randomized phase 3 clinical trial in patients with secondary progressive multiple sclerosis (SPMS), 2016.

A. J. Coles, A. Cox, L. Page, E. Jones, J. Trip et al., The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy, J Neurol, vol.253, issue.1, pp.98-108, 2006.

B. Brochet, M. Deloire, P. Perez, T. Loock, L. Baschet et al., Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis, PLoS ONE, vol.12, issue.1, p.168834, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01792762

X. Montalban, S. L. Hauser, L. Kappos, D. L. Arnold, A. Bar-or et al., Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
DOI : 10.1056/nejmoa1606468

URL : https://hal.archives-ouvertes.fr/hal-01793440

, N Engl J Med, vol.376, issue.3, pp.209-229, 201719.

T. L. Vollmer, P. S. Sorensen, K. Selmaj, F. Zipp, E. Havrdova et al., A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis, J Neurol, vol.261, issue.4, pp.773-83, 2014.

G. Comi, D. Jeffery, L. Kappos, X. Montalban, A. Boyko et al., Placebo-controlled trial of oral laquinimod for multiple sclerosis, N Engl J Med, vol.366, issue.11, pp.1000-1009, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00826733

L. Kappos, A. Bar-or, B. Cree, R. J. Fox, G. Giovannoni et al., Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND):a double-blind, randomised, phase 3 study. The Lancet, vol.391, pp.1263-73, 2018.

R. Kapoor, J. Furby, T. Hayton, K. J. Smith, D. R. Altmann et al., Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial, Lancet Neurol, 2010.

J. Zajicek, S. Ball, D. Wright, J. Vickery, A. Nunn et al., Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial, Lancet Neurol, vol.12, issue.9, pp.857-65, 2013.

M. Cambron, Fluoxetine in progressive multiple sclerosis (FLUOX-PMS)

, Communication orale ECTRIMS, 2016.

J. Chataway, N. Schuerer, A. Alsanousi, D. Chan, D. Macmanus et al., Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised

, Lancet, vol.383, issue.9936, pp.2213-2234, 2014.

F. Sedel, C. Papeix, A. Bellanger, V. Touitou, C. Lebrun-frenay et al., High doses of biotin in chronic progressive multiple sclerosis: A pilot study
URL : https://hal.archives-ouvertes.fr/hal-01251510

, Multiple Sclerosis and Related Disorders, vol.4, pp.159-69, 2015.

A. Tourbah, C. Lebrun-frenay, G. Edan, M. Clanet, C. Papeix et al., MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study, Mult Scler, vol.22, issue.13, pp.1719-1750, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02153440

D. Cadavid, L. Balcer, S. Galetta, O. Aktas, T. Ziemssen et al., Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial, Lancet Neurol, vol.16, issue.3, pp.189-99, 2017.

D. Cadavid, Efficacy analysis of opicinumab in relapsing multiple sclerosis: the Phase 2b SYNERGY trial, Communication orale ECTRIMS, 2016.

M. Koch, An open label, single arm, phase II futility trial of Domperidone treatment in secondary progressive MS. Results of the first stage of the trial, Communication orale ECTRIMS, 2017.

A. J. Green, J. M. Gelfand, B. A. Cree, C. Bevan, W. J. Boscardin et al., Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial, Lancet, vol.390, pp.2481-2490, 2017.